Global T-Cell Therapy Market by Modality (Research, and Commercialized), By Therapy (CAR T-Cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes), By Indication (Hematologic Malignancies (Lymphoma, Leukemia, and Myeloma) and Solid Tumors (Melanoma, Brain & Central Nervous System, Liver cancer and others)), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa)

Global t-cell therapy market likely to propelling due to the rise in prevalence of cancer across the globe
Global T-cell therapy market estimated to grow with a CAGR of over 12.4% during the forecast period, 2020-2027. It is primarily attributed to the rising prevalence of cancer across the world and an increase in cancer research & development across the globe. According to WHO, around 70% of deaths from cancer occur in low-and middle-income countries, and also WHO stated that, by 2030, approximately 10 to 11 million cases of cancers would be diagnosed each year in low-and middle-income countries. Additionally, the increasing network of diverse CAR-T/TCR developers with their products offering will accelerate the t-cell therapy market size in the forecast timeline. In 2019, the U.S. Center for Medical Insurance and Medicaid Services (CMS) approved for medical insurance for T-cell therapy. Moreover, technological advancements in developments and processes in CAR T-cell therapy for solid tumors and the approvals and clinical success of Kymriah and Yescarta will fuel the robust growth of the t-cell therapy industry in the projected time. T-cell therapy uses immune cells extracted from the patients blood to recompile them to identify and attack specific proteins found in brain tumors, and then re-import the immune cells into the patients body system.
 

Furthermore, the surge in the number of patients presenting a failure response to alternative therapies coupled with the increasing occurrence of cancer cases across the globe will spur the global T-cell therapy market share in the future periods. Also, high cancer cases around the world projected to raise the demand for a reliable and effective therapeutic treatment approach that will augment the global t-cell therapy industry in the next few years.
 

Therapy Type Overview in the Global T-cell therapy Market
Based on therapy type, the global t-cell therapy market classified into CAR T-Cell Therapy, T Cell Receptor (TCR), and Tumor-Infiltrating Lymphocytes. The CAR T-Cell Therapy segment will be the fastest-growing segment in the forecast period. It is attributable to the effectiveness of CAR-T cell therapy, such that it has higher efficacy than other therapies currently available on the market for the treatment of cancer. The ability of CAR to integrate onto the surface of T cells, primarily when delivered by monoclonal antibodies, promotes T cells to more easily penetrate cancer-causing cells of patients.
T Cell Receptor (TCR) will grow at a significant rate in the forecast period. It is due to the T cell receptor (TCR) used for leukemia or other tumor cells.
 

Modality Overview in the Global T-cell therapy market
Based on modality, the global t-cell therapy market bifurcated into Research and Commercialized. The Commercialized will be the fastest-growing segment in the forecast period owing to the investment by start-up companies in treatment technologies of cancer diseases and approval of cell therapy by the USA and European Union.
 

Indication Overview in the Global T-cell therapy Market
Based on the indication, the global t-cell therapy market bifurcates into Hematologic Malignancies (Lymphoma, Leukemia, and Myeloma) and Solid Tumors (Melanoma, Brain & Central Nervous System, Liver cancer and others). The Hematologic Malignancies segment accounted for a larger market share in 2019 and projected to lead the market by 2027. It is due to t-cell therapy demand for the treatment of Lymphoma, Leukemia, and Myeloma.
Solid Tumors will grow with a lucrative rate during the analysis timespan owing to advanced t-cell therapy techniques find a way for the treatment of Melanoma, Brain & Central Nervous System, and Liver cancer.
 

Regional Overview in the Global T-cell therapy Market
By geography, the Global T-cell therapy Market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America accounted for maximum revenue share in 2019, owing to the presence of keys players in these regions, the large number of research institute presence coupled with the approval of t-cell therapy in the U.S. and Canada by FDA.
 

Global T-cell therapy Market: Competitive Landscape
Companies such as Novartis AG, Gilead Sciences, bluebird bio, TCR2 Therapeutics Inc., Sorrento Therapeutics, Kite Pharma, Merck KGaA, Pfizer, Amgen, Celgene Corporation and Fate Therapeutics are the key players in the Global T-Cell Therapy Market.

Global T-cell Therapy Market
Report Content
1. Research Strategic Development
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
2. Research Methodology
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
3. Executive Summary
4. Market Insights
4.1. Economic Factor Analysis
4.1.1. Drivers
4.1.2. Trends
4.1.3. Opportunities
4.1.4. Challenges
4.2. Technological Landscape
4.3. Competitors & Product Analysis
4.4. Regulatory Framework
4.5. Company market share analysis, 2019
4.6. Porter’s Five forces analysis
4.7. New Investment Analysis
4.8. PESTEL Analysis
5. Global T-cell Therapy Market Overview
5.1. Market Size & Forecast, 2016-2027
5.1.1. Demand
5.1.1.1. By Value (USD Million)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Modality
5.2.1.1. Research
5.2.1.2. Commercialized
5.2.2. By Therapy Type
5.2.2.1. CAR T-Cell Therapy
5.2.2.2. T Cell Receptor (TCR)
5.2.2.3. Tumor Infiltrating Lymphocytes
5.2.3. By Indication
5.2.3.1. Hematologic Malignancies
5.2.3.1.1. Lymphoma
5.2.3.1.2. Leukemia
5.2.3.1.3. Myeloma
5.2.3.2. Solid Tumors
5.2.3.2.1. Melanoma
5.2.3.2.2. Brain & Central Nervous System
5.2.3.2.3. Liver cancer
5.2.3.2.4. Others
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. Asia Pacific
5.2.4.4. South America
5.2.4.5. Middle East & Africa
6. North America T-cell Therapy Market Overview
6.1. North America T-cell Therapy Market Size & Forecast, 2016-2027
6.1.1. Demand
6.1.1.1. By Value (USD Million)
6.2. North America T-cell Therapy Market Share & Forecast, 2016-2027
6.2.1. By Modality
6.2.1.1. Research
6.2.1.2. Commercialized
6.2.2. By Therapy Type
6.2.2.1. CAR T-Cell Therapy
6.2.2.2. T Cell Receptor (TCR)
6.2.2.3. Tumor Infiltrating Lymphocytes
6.2.3. By Indication
6.2.3.1. Hematologic Malignancies
6.2.3.1.1. Lymphoma
6.2.3.1.2. Leukemia
6.2.3.1.3. Myeloma
6.2.3.2. Solid Tumors
6.2.3.2.1. Melanoma
6.2.3.2.2. Brain & Central Nervous System
6.2.3.2.3. Liver cancer
6.2.3.2.4. Others
6.2.4. By Country
6.2.4.1. US
6.2.4.2. Canada
6.2.4.3. Mexico
6.2.5. Company Market Share (Top 3-5)
6.2.6. Economic Impact Study on North America T-cell Therapy Market
7. Europe T-cell Therapy Market Overview
7.1. Europe T-cell Therapy Market Size & Forecast, 2016-2027
7.1.1. Demand
7.1.1.1. By Value (USD Million)
7.2. Europe T-cell Therapy Market Share & Forecast, 2016-2027
7.2.1. By Modality
7.2.1.1. Research
7.2.1.2. Commercialized
7.2.2. By Therapy Type
7.2.2.1. CAR T-Cell Therapy
7.2.2.2. T Cell Receptor (TCR)
7.2.2.3. Tumor Infiltrating Lymphocytes
7.2.3. By Indication
7.2.3.1. Hematologic Malignancies
7.2.3.1.1. Lymphoma
7.2.3.1.2. Leukemia
7.2.3.1.3. Myeloma
7.2.3.2. Solid Tumors
7.2.3.2.1. Melanoma
7.2.3.2.2. Brain & Central Nervous System
7.2.3.2.3. Liver cancer
7.2.3.2.4. Others
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. UK
7.2.4.3. France
7.2.4.4. Italy
7.2.4.5. Rest of Europe
7.2.5. Company Market Share (Top 3-5)
7.2.6. Economic Impact Study on Europe T-cell Therapy Market
8. Asia Pacific T-cell Therapy Market Overview
8.1. Asia Pacific T-cell Therapy Market Size & Forecast, 2016-2027
8.1.1. Demand
8.1.1.1. By Value (USD Million)
8.2. Asia Pacific T-cell Therapy Market Share & Forecast, 2016-2027
8.2.1. By Modality
8.2.1.1. Research
8.2.1.2. Commercialized
8.2.2. By Therapy Type
8.2.2.1. CAR T-Cell Therapy
8.2.2.2. T Cell Receptor (TCR)
8.2.2.3. Tumor Infiltrating Lymphocytes
8.2.3. By Indication
8.2.3.1. Hematologic Malignancies
8.2.3.1.1. Lymphoma
8.2.3.1.2. Leukemia
8.2.3.1.3. Myeloma
8.2.3.2. Solid Tumors
8.2.3.2.1. Melanoma
8.2.3.2.2. Brain & Central Nervous System
8.2.3.2.3. Liver cancer
8.2.3.2.4. Others
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. Australia
8.2.4.5. Rest of Asia Pacific
8.2.5. Company Market Share (Top 3-5)
8.2.6. Economic Impact Study on Asia Pacific T-cell Therapy Market
9. South America T-cell Therapy Market Overview
9.1. South America T-cell Therapy Market Size & Forecast, 2016-2027
9.1.1. Demand
9.1.1.1. By Value (USD Million)
9.2. South America T-cell Therapy Market Share & Forecast, 2016-2027
9.2.1. By Modality
9.2.1.1. Research
9.2.1.2. Commercialized
9.2.2. By Therapy Type
9.2.2.1. CAR T-Cell Therapy
9.2.2.2. T Cell Receptor (TCR)
9.2.2.3. Tumor Infiltrating Lymphocytes
9.2.3. By Indication
9.2.3.1. Hematologic Malignancies
9.2.3.1.1. Lymphoma
9.2.3.1.2. Leukemia
9.2.3.1.3. Myeloma
9.2.3.2. Solid Tumors
9.2.3.2.1. Melanoma
9.2.3.2.2. Brain & Central Nervous System
9.2.3.2.3. Liver cancer
9.2.3.2.4. Others
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Argentina
9.2.4.3. Rest of South America
9.2.5. Company Market Share (Top 3-5)
9.2.6. Economic Impact Study on South America T-cell Therapy Market
10. Middle East & Africa T-cell Therapy Market Overview
10.1. Middle East & Africa T-cell Therapy Market Size & Forecast, 2016-2027
10.1.1. Demand
10.1.1.1. By Value (USD Million)
10.2. Middle East & Africa T-cell Therapy Market Share & Forecast, 2016-2027
10.2.1. By Modality
10.2.1.1. Research
10.2.1.2. Commercialized
10.2.2. By Therapy Type
10.2.2.1. CAR T-Cell Therapy
10.2.2.2. T Cell Receptor (TCR)
10.2.2.3. Tumor Infiltrating Lymphocytes
10.2.3. By Indication
10.2.3.1. Hematologic Malignancies
10.2.3.1.1. Lymphoma
10.2.3.1.2. Leukemia
10.2.3.1.3. Myeloma
10.2.3.2. Solid Tumors
10.2.3.2.1. Melanoma
10.2.3.2.2. Brain & Central Nervous System
10.2.3.2.3. Liver cancer
10.2.3.2.4. Others
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. UAE
10.2.4.3. South Africa
10.2.4.4. Rest of Middle East & Africa
10.2.5. Company Market Share (Top 3-5)
10.2.6. Economic Impact Study on Middle East & Africa T-cell Therapy Market
11. Competitor Analysis
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. Novartis AG
11.7.2. Gilead Sciences
11.7.3. bluebird bio
11.7.4. TCR2 Therapeutics Inc.
11.7.5. Sorrento Therapeutics
11.7.6. Kite Pharma
11.7.7. Merck KGaA
11.7.8. Pfizer
11.7.9. Amgen
11.7.10. Celgene Corporation
11.7.11. Fate Therapeutics
11.7.12. Other Prominent Players

Fill The Form For Sample Request

There is no Reviews available